TORONTO, April 08, 2019 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V: DXD) (the “Company” or “3DS”) is pleased to announce that it has changed its corporate name to Telo Genomics Corp. effective April 08, 2019. Effective at the opening of trading on April 08, 2019, the common shares of the Company will commence trading on the TSX Venture Exchange under the new name.
Concomitant with the name change the Company has changed its stock symbol on TSX Venture Exchange to TELO and launched a new website www.telodx.com. The Company’s mailing address and phone number will remain unchanged.
The Company's Board of Directors has determined that changing the Company name will assist in its rebranding, reorganization and refinancing objectives. On February 28, 2019 during the Company’s annual general and special meeting the shareholders voted in favour to the name change and authorized the Board of Directors to effectuate when possible.
Shareholders holding 3D Signatures share certificates can request a replacement certificate with the new Company name, but new certificates are not required and will not be automatically issued.
For more information, visit the Company’s website at http://www.telodx.com
For further information, please contact:
Hugh Rogers
Chairman
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward- looking statements regarding the name change and the ability of the TeloViewTM platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.